Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986360 alone and in combination in advanced solid tumors
NCT05625412Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, randomised, open-label trial of CC-90001 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and 5 more (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with Adverse Events (AEs), Number of participants with Serious Adverse Events (SAEs) and 3 more. Started Dec 2022; status: completed.
02
Drugs
CC-90001
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)squamous cell carcinoma of the head and neck (HNSCC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05625412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625412.